Johns Hopkins Medicine

The FDA has just cleared a blood test to help make the diagnosis of Alzheimer’s disease, which otherwise may require some fairly invasive methods. Blood biomarkers expert Abhay Moghekar, a neurologist at Johns Hopkins, says the test looks for the …

Who is a candidate for the new blood test for Alzheimer’s disease? Elizabeth Tracey reports Read More »

A blood test to screen for proteins related to Alzheimer’s disease has been cleared by the FDA, and it’s designed for people who are older than 55 years of age and have cognitive symptoms. Johns Hopkins neurologist Abhay Moghekar, a …

What’s the basis of the new blood test to screen for Alzheimer’s disease? Elizabeth Tracey reports Read More »

Across large healthcare systems, the unexpected death of a colleague can be disruptively sad, but isn’t necessarily an uncommon event. Join a conversation between Jonathan Ripp and Lee Biddison on coordinating support for team members who have experienced the loss …

Ep. 15 When a Colleague Dies Unexpectedly: Considerations for an Institutional Response | Johns Hopkins Medicine Office of Well-Being Read More »

NPTX2 is a protein that’s pivotal for helping your brain decide to remember certain things and forget others, and when levels of it decline it suggests that neurodegenerative processes like dementia may be beginning. That’s according to research by Paul …

A protein that’s made in your brain at night helps you remember things, Elizabeth Tracey reports Read More »

Many theories on how brain disorders like Alzheimer’s disease begin point to proteins called amyloid beta and tau as accumulating and disrupting the function of neurons. Research by neuroscientist Paul Worley and colleagues at Johns Hopkins points to declining levels …

How do neurodegenerative diseases begin? Elizabeth Tracey reports Read More »

You probably know how complex your brain function is, relying on a delicately balanced system full of proteins that act as signals and specialized nerve and structural cells. Turns out there is an interplay of some neurons being shut down …

A change in a protein in the brain signals possible neurocognitive disorders, Elizabeth Tracey reports Read More »

NPTX2 is the abbreviation for a protein found in the brain that may allow much more accurate prognosis of who’s at risk for developing neurocognitive disorders, including Alzheimer’s disease and other dementias. That’s according to Johns Hopkins neuroscientist Paul Worley, …

Accurately predicting who’s at risk to develop Alzheimer’s disease may now be easier, Elizabeth Tracey reports Read More »

Proteins known as tau and beta amyloid have been part of the dialogue on Alzheimer’s disease development for many years, with methods to measure them and drugs to remove them active areas of research. Another protein involved in the process …

What can proteins in the blood and elsewhere teach us about developing dementia? Elizabeth Tracey reports Read More »

Sickle cell disease was thought to be cured using gene therapy, but longer term follow up reveals that while the condition improves many are not cured. Now a new approach developed at Johns Hopkins and around the world uses ‘half-matched’ …

Sickle cell disease should be treated with a half-matched donor approach, Elizabeth Tracey reports Read More »

Gene therapy for sickle cell disease has a breathtaking price tag of 2-3 million dollars per person, and for some people who receive it, is doesn’t actually cure the condition. That’s according to Richard Brodsky, a sickle cell expert at …

Gene therapy for sickle cell disease often isn’t a cure, Elizabeth Tracey reports Read More »